Patent: 8,912,148
✉ Email this page to a colleague
Summary for Patent: 8,912,148
Title: | Methods of treating a disease or condition associated with abnormal angiogenesis |
Abstract: | The present invention provides methods of treating (including preventing) a disease or condition associated with abnormal angiogenesis in a subject include administering a therapeutically effective amount of an AA targeting compound of the invention to the subject. The AA targeting compounds comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. |
Inventor(s): | Bradshaw; Curt (San Diego, CA), Bhat; Abhijit (Encinitas, CA), Lai; Jing Yu (San Diego, CA), Doppalapudi; Venkata (San Diego, CA), Liu; Dingguo (San Diego, CA) |
Assignee: | Covx Technology Ireland, Ltd. (Dublin, IE) |
Application Number: | 13/584,721 |
Patent Claims: | see list of patent claims |
Details for Patent 8,912,148
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2026-11-10 |
Amgen, Inc. | EPOGEN/PROCRIT | epoetin alfa | Injection | 103234 | 06/01/1989 | ⤷ Try a Trial | 2026-11-10 |
Amgen, Inc. | EPOGEN/PROCRIT | epoetin alfa | Injection | 103234 | ⤷ Try a Trial | 2026-11-10 | |
Amgen, Inc. | PROCRIT | epoetin alfa | Injection | 103234 | ⤷ Try a Trial | 2026-11-10 | |
Clinigen, Inc. | PROLEUKIN | aldesleukin | For Injection | 103293 | 05/05/1992 | ⤷ Try a Trial | 2026-11-10 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |